Bioliberty
Bioliberty is an Edinburgh-based medtech company providing upper-limb rehabilitation for stroke and neurological patients.
Position in SVTRnew
Snapshot 2026-11-04- Startup SignalsRankedof 2,311
- Life SciencesRankedof 244
- Medtech DeviceRankedof 47
About
Bioliberty is an Edinburgh-based medtech company providing upper-limb rehabilitation for stroke and neurological patients. Its Lifeglov soft robotic glove, AI-powered Lifehub Clinic platform and Lifemind clinician dashboard help therapists deliver higher-intensity therapy while objectively tracking recovery. The products are FDA-registered and the company has a US office in Boston.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 1
Investor· 4
Founders / team· 4
Funding history
- 2026-11-02Series A$3M
Investors · TGH Ventures, Ballad Ventures, 25m Health, WhiterockSource · finsmes.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Bioliberty
Bioliberty is an Edinburgh-based medtech company providing upper-limb rehabilitation for stroke and neurological patients.
Series A · 2026-11
—
United States
BusinessLatest roundTotal raisedDate- Blue Arbor Technologies
Implantable neuromuscular interface (RESTORE system) for intuitive prosthetic control by upper-limb amputees
Series A · 2026-10
— - Monteris Medical
Develops robotically controlled, MR-guided laser ablation systems for minimally invasive brain surgery
Series D+ · $178M · 2026-03
$178M - Overture Life
Robotic IVF devices that automate handling and preparation of eggs and embryos
Undisclosed · $21M · 2025-04
$21M
China
BusinessLatest roundTotal raisedDate- 德壹医疗
AI physiotherapy robots for tuina massage, moxibustion, shockwave therapy and more, used by TCM hospitals…
Series A · 2026-07
— - 深度医疗
R&D and manufacturing of the FUNZAR microsurgery robot for hospital ophthalmology, orthopedics, neurosurgery, plastic surgery and other departments…
Series B · 2026-10
— - 思博慧医
Fully autonomous magnetically guided neurointerventional surgical robot driven by a VLA large model
Series A · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Vitestro
Developed a device that integrates AI with ultrasound imaging and robotics to automate blood collection
Series B · $120M · 2026-03
$120M - Nami Surgical
Miniature ultrasonic medical devices for surgery; high-performance small ultrasonic scalpels designed to overcome obstacles in robot-assisted surgery
Undisclosed · $4M · 2024-05
$4M - Soundsafe Care
Robotic focused ultrasound devices for noninvasive tumor ablation, launching first with veterinary certification…
$2M
$2M
Other / unspecified
BusinessLatest roundTotal raisedDate- Scopia Surgical
AI surgical navigation software combining real-time spatial intelligence and patient-specific digital twins for robot-assisted and minimally invasive …
Pre-Seed · $3M · 2026-09
$3M - IMeditech
R&D and manufacturing of electrospun nanofiber wound care devices, vascular stents, catheters and neurointerventional devices…
$1.1B
$1.1B - iPreg Inc.
Assisted reproduction devices: SperSort™ biomimetic antibody-free microfluidic sperm sorting chip and companion equipment for fertility centers; also …
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 34 at a nearby stage · 3 in Western Europe
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 24 at a nearby stage · 1 in Western Europe
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 10 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 9 at a nearby stage · 3 in Western Europe
Request intro →GV
12 Life Sciences deals in the last 24 months · 6 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.